ChinaMart

China Biotech Week in Review: Earnings, Deals and Drug Development

LTUS (Lotus Pharmaceuticals) reaffirmed 2008 guidance on Friday. That guidance of $13.8M USD in net income is about .29/share fully diluted...making the PE for LTUS well under 4.
As far as I can tell, this makes LTUS the best value in the China Biopharma sector today.

Sinovac’s Q1 Doubles Year-Earlier Results

LTUS reports early next week, and should have excellent results as well. I'm still amazed that the Jim rogers types aren't talking about China pharmas- they're all about ag., travel, energy, and online. But the China pharma sector is growing 20% (or more) yoy, and there are less pharmas competing for that bigger pie due to rapid consolisation. This puts them in an excellent position to continue to report the kind of growth we've seen so far in 2008 for the rest of the year IMO, and makes them among the most attractive of China investments right now.